

External Quality Assessment Scheme

Coeliac disease, antibodies Round 1, 2023

Specimens

Please find enclosed 2 human plasma or serum samples S001 and S002, each 0.7 mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations (Scheme is not suitable for POC tests)

EMAAbA	Endomysium antibody, IgA
EMAAbG	Endomysium antibody, IgG
tTGAba	Tissue transglutaminase antibody, IgA
tTGAbG	Tissue transglutaminase antibody, IgG
DGPAb	Deamidated gliadin peptide antibody
DGPAbA	Deamidated gliadin peptide antibody, IgA
DGPAbG	Deamidated gliadin peptide antibody, IgG

Interpretation of the total IgA concentration of the sample

Storage and use

After arrival, the samples should be stored at +2...8 °C, and used as soon as possible, preferably within a week. The samples are ready for use. Analyse as patient samples.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator.

S001



S002



2023-02-21

INSTRUCTIONS

Product no. 5940
LQ717423011-012/FI

Subcontracting: Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **March 17, 2023.**

The expected results of the round are published in LabScala in the View Reports section by March 21, 2023.

Inquiries

EQA Coordinator
Mira Saarinen
mira.h.saarinen@labquality.fi

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



Only the analysis phase is accredited.





tTGAbA | Phadia 1-2

Sample S001

Methodics	Positive	Total
Bio-Rad BioPlex 2200 Celiac IgA	1	1
Chorus tTG	3	3
CIA, Inova	1	1
EIA Transglutaminase, TestLine	1	1
EliA/ImmunoCAP, Phadia	33	33
ELISA, D-tek	1	1
ELISA, Euroimmun	4	4
ELISA, Inova	1	1
ELISA, Orgentec	6	6
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgA	1	1
TestLine CLIA Transglutaminase IgA	1	1
TestLine EIA Transglutaminase IgA	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	55	55

Sample S002

Methodics	Negative	Total
Bio-Rad BioPlex 2200 Celiac IgA	1	1
Chorus tTG	3	3
CIA, Inova	1	1
EIA Transglutaminase, TestLine	1	1
EliA/ImmunoCAP, Phadia	33	33
ELISA, D-tek	1	1
ELISA, Euroimmun	4	4
ELISA, Inova	1	1
ELISA, Orgentec	6	6
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgA	1	1
TestLine CLIA Transglutaminase IgA	1	1
TestLine EIA Transglutaminase IgA	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	55	55



	x_{pt}	sd	SEM	CV%	n
EliA/ImmunoCAP, Phadia	34.8 U/ml	5.0	0.9	14.4	33
All methods	41.0 U/ml	24.5	3.6	59.7	49

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Sample S001	34.8	35.0	0.4%	0.03
22/3	Sample S002	125.7	129.0	2.6%	-
22/3	Sample S001	0.4	0.7	100.0%	2.49
22/2	Sample S001	169.0	129.0	-23.7%	-0.50
22/1	Sample S002	110.5	124.0	12.2%	0.76

DGPAbG | Phadia 1-2


Sample S001

Methodics	Positive	Total
Bio-Rad BioPlex 2200 Celiac IgG	1	1
CIA, Inova	1	1
EIA Gliadin DA, TestLine	1	1
EliA/ImmunoCAP, Phadia	24	24
ELISA, Euroimmun	2	2
ELISA, Inova	2	2
ELISA, Orgentec	4	4
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgG	1	1
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
TestLine CLIA Gliadin DA IgG	1	1
TestLine EIA Gliadin DA IgG	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	40	40


Sample S002

Methodics	Positive	Total
Bio-Rad BioPlex 2200 Celiac IgG	1	1
CIA, Inova	1	1
EIA Gliadin DA, TestLine	1	1
EliA/ImmunoCAP, Phadia	24	24
ELISA, Euroimmun	2	2
ELISA, Inova	2	2
ELISA, Orgentec	4	4
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgG	1	1
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
TestLine CLIA Gliadin DA IgG	1	1
TestLine EIA Gliadin DA IgG	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	40	40


Sample S001-DGPAbG



Sample S002-DGPAbG



History



	x_{pt}	sd	SEM	CV%	n
EliA/ImmunoCAP, Phadia	312.0 U/ml	91.0	32.2	29.2	8
All methods	251.9 U/ml	103.1	27.6	40.9	15

	x_{pt}	sd	SEM	CV%	n
EliA/ImmunoCAP, Phadia	338.5 U/ml	182.0	74.3	53.8	6
All methods	267.3 U/ml	158.2	45.7	59.2	12

Round	Sample	x_{pt}	Result	diff%	z-score
23/1	Sample S002	338.5	303.0	-10.5%	-0.20
23/1	Sample S001	312.0	303.0	-2.9%	-0.10
22/3	Sample S002	25.5	26.0	2.0%	0.11
22/2	Sample S002	353.3	303.0	-14.2%	-0.69
22/2	Sample S001	32.7	35.0	7.2%	0.32
22/1	Sample S002	302.0	303.0	0.3%	-

Report info**Participants**

58 participants from 14 countries.

Report info

Qualitative and quantitative results are presented in the same report. Always compare your results to those obtained with the same test kit.

The qualitative results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green colour and laboratory's own result with a black radio button .

The quantitative results from the positive specimens are presented as histograms. Quantitative results reported with < or > -signs are not processed. Results reported as ratios, titres, absorbances and without a unit are manually removed and not statistically processed.

Assigned values (target values) are mean of the results where results deviating more than ± 3 standard deviation from the median are removed. The standard uncertainty (u) of the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected". In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated.

In participant specific report your own result is shown with an orange dot. The target area is presented as a yellow area in the picture. In the history graphs you are able to see your performance graphically with both against the assigned value (xpt) and the z-score area of -2 ... +2.

If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EOA Coordinator.

Sample S001 | EMAbA, -

Methodics	Negative	Weak positive	Positive	Total
Euroimmun Coeliac diseaseScreen EuroPattern endomysium	-	-	1	1
IFA Euroimmun	-	-	8	8
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	-	-	1	1
IFA NOVA Lite	1	2	4	7
Total	1	2	14	17

Sample S001 | EMAbG, -


Methodics	Positive	Total
IFA Euroimmun	6	6
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
IFA NOVA Lite	6	6
Total	13	13

Sample S001 | tTGAbA, U/ml

Methodics	Positive	Total
Bio-Rad BioPlex 2200 Celiac IgA	1	1
Chorus tTG	3	3
CIA, Inova	1	1
EIA Transglutaminase, TestLine	1	1
EliA/ImmunoCAP, Phadia	33	33
ELISA, D-tek	1	1
ELISA, Euroimmun	4	4
ELISA, Inova	1	1
ELISA, Orgentec	6	6
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgA	1	1
TestLine CLIA Transglutaminase IgA	1	1
TestLine EIA Transglutaminase IgA	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	55	55


Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Rad BioPlex 2200 Celiac IgA	-	-	-	-	-	251.0	251.0	-	1
Chorus tTG	44.1	44.1	15.6	35.5	11.1	33.0	55.1	-	2
CIA, Inova	-	-	-	-	-	303.1	303.1	-	1
EIA Transglutaminase, TestLine	-	-	-	-	-	58.1	58.1	-	1
EliA/ImmunoCAP, Phadia	34.8	34.0	5.0	14.4	0.9	25.0	45.0	-	33
ELISA, D-tek	-	-	-	-	-	327.7	327.7	-	1
ELISA, Euroimmun	-	-	-	-	-	192.0	192.0	-	1
ELISA, Inova	-	-	-	-	-	28.4	28.4	-	1
ELISA, Orgentec	40.9	39.0	4.8	11.8	2.0	36.5	47.6	-	6
TestLine CLIA Transglutaminase IgA	-	-	-	-	-	76.8	76.8	-	1
Theradiag FIDIS CELIAC DGP	-	-	-	-	-	48.0	48.0	-	1
All	41.0	36.0	24.5	59.7	3.6	25.0	192.0	3	49

Bio-Rad BioPlex 2200 Celiac IgA












■ All method groups ■ Bio-Rad BioPlex 2200 Celiac IgA

Chorus tTG



■ All method groups ■ Chorus tTG xxx (x_{pt} : 44.1 | Target area: 35.2-52.9 | Target: $\pm 20\%$)










Sample S001 | tTGAbG, U/ml


Methodics	Borderline	Weak positive	Positive	Total
Chorus tTG	-	-	1	1
EIA Transglutaminase, TestLine	-	-	1	1
EliA/ImmunoCAP, Phadia	-	-	17	17
ELISA, Euroimmun	1	1	1	3
ELISA, Inova	-	-	2	2
ELISA, Orgentec	-	-	6	6
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgG	-	-	1	1
TestLine CLIA Transglutaminase IgG	-	-	1	1
TestLine EIA Transglutaminase IgG	-	-	1	1
Theradiag FIDIS CELIAC DGP	-	-	1	1
Total	1	1	32	34

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
EIA Transglutaminase, TestLine	-	-	-	-	-	37.6	37.6	-	1
EliA/ImmunoCAP, Phadia	61.5	62.0	6.2	10.0	1.5	51.0	72.0	-	17
ELISA, Inova	-	-	-	-	-	97.1	97.1	-	1
ELISA, Orgentec	98.3	89.7	45.8	46.6	18.7	47.8	182.5	-	6
TestLine CLIA Transglutaminase IgG	-	-	-	-	-	79.8	79.8	-	1
Theradiag FIDIS CELIAC DGP	-	-	-	-	-	84.0	84.0	-	1
All	67.3	65.0	16.0	23.7	3.1	37.6	106.9	1	27





■ All method groups ■ TestLine CLIA Transglutaminase IgG










■ All method groups ■ Theradiag FIDIS CELIAC DGP

Sample S001 | DGPAbA, U/ml

Methodics	Negative	Borderline	Weak positive	Positive	Total
EIA Gliadin DA, TestLine	-	1	-	-	1
EliA/ImmunoCAP, Phadia	-	5	1	11	17
ELISA, Euroimmun	-	-	-	2	2
ELISA, Inova	-	-	-	1	1
ELISA, Orgentec	3	-	-	-	3
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgA	-	-	-	1	1
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	-	-	-	1
TestLine CLIA Gliadin DA IgA	1	-	-	-	1
TestLine EIA Gliadin DA IgA	1	-	-	-	1
Theradiag FIDIS CELIAC DGP	-	-	1	-	1
Total	6	6	2	15	29

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
EIA Gliadin DA, TestLine	-	-	-	-	-	25.9	25.9	-	1
EliA/ImmunoCAP, Phadia	11.3	11.0	1.9	16.4	0.5	7.4	15.0	-	17
ELISA, Euroimmun	70.1	70.1	18.3	26.1	12.9	57.2	83.0	-	2
ELISA, Inova	-	-	-	-	-	49.3	49.3	-	1
ELISA, Orgentec	9.4	8.8	1.9	20.4	1.1	7.8	11.5	-	3
TestLine CLIA Gliadin DA IgA	-	-	-	-	-	13.1	13.1	-	1
Theradiag FIDIS CELIAC DGP	-	-	-	-	-	27.0	27.0	-	1
All	15.7	12.0	12.2	77.8	2.4	7.4	57.2	1	26













Sample S001 | DGPAbG, U/ml

Methodics	Positive	Total
Bio-Rad BioPlex 2200 Celiac IgG	1	1
CIA, Inova	1	1
EIA Gliadin DA, TestLine	1	1
EliA/ImmunoCAP, Phadia	24	24
ELISA, Euroimmun	2	2
ELISA, Inova	2	2
ELISA, Orgentec	4	4
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgG	1	1
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
TestLine CLIA Gliadin DA IgG	1	1
TestLine EIA Gliadin DA IgG	1	1
Therdiag FIDIS CELIAC DGP	1	1
Total	40	40

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Rad BioPlex 2200 Celiac IgG	-	-	-	-	-	250.0	250.0	-	1
CIA, Inova	-	-	-	-	-	900.6	900.6	-	1
EIA Gliadin DA, TestLine	-	-	-	-	-	200.0	200.0	-	1
EliA/ImmunoCAP, Phadia	312.0	303.0	91.0	29.2	32.2	131.9	456.0	-	8
ELISA, Inova	-	-	-	-	-	150.0	150.0	-	1
ELISA, Orgentec	-	-	-	-	-	175.0	175.0	-	1
TestLine CLIA Gliadin DA IgG	-	-	-	-	-	100.2	100.2	-	1
Therdiag FIDIS CELIAC DGP	-	-	-	-	-	155.0	155.0	-	1
All	251.9	275.0	103.1	40.9	27.6	100.2	456.0	1	15





Sample S001 | Total IgA concentration of the sample

	n
Sufficient to determine specific coeliac IgA antibodies	16
Probably insufficient to determine specific coeliac IgA antibodies	1
Total IgA concentration was not determined	20
Total	37

Sample S002 | EMAbA, -

Methodics	Negative	Total
Euroimmun Coeliac diseaseScreen EuroPattern endomysium	1	1
IFA Euroimmun	8	8
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
IFA NOVA Lite	7	7
Total	17	17

Sample S002 | EMAbG, -

Methodics	Positive	Total
IFA Euroimmun	6	6
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
IFA NOVA Lite	6	6
Total	13	13





Sample S002 | tTGAbA, U/ml



Methodics	Negative	Total
Bio-Rad BioPlex 2200 Celiac IgA	1	1
Chorus tTG	3	3
CIA, Inova	1	1
EIA Transglutaminase, TestLine	1	1
EliA/ImmunoCAP, Phadia	33	33
ELISA, D-tek	1	1
ELISA, Euroimmun	4	4
ELISA, Inova	1	1
ELISA, Orgentec	6	6
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgA	1	1
TestLine CLIA Transglutaminase IgA	1	1
TestLine EIA Transglutaminase IgA	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	55	55

Sample S002 | tTGAbG, U/ml

Methodics	Negative	Positive	Total
Chorus tTG	-	1	1
EIA Transglutaminase, TestLine	-	1	1
EliA/ImmunoCAP, Phadia	-	18	18
ELISA, Euroimmun	-	3	3
ELISA, Inova	-	2	2
ELISA, Orgentec	1	5	6
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgG	-	1	1
TestLine CLIA Transglutaminase IgG	-	1	1
TestLine EIA Transglutaminase IgG	-	1	1
Theradiag FIDIS CELIAC DGP	-	1	1
Total	1	34	35

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
EIA Transglutaminase, TestLine	-	-	-	-	-	200.0	200.0	-	1
EliA/ImmunoCAP, Phadia	493.5	494.0	49.0	9.9	11.9	434.0	624.0	-	17
ELISA, Inova	-	-	-	-	-	100.0	100.0	-	1
ELISA, Orgentec	-	-	-	-	-	2976.0	2976.0	-	1
TestLine CLIA Transglutaminase IgG	-	-	-	-	-	149.5	149.5	-	1
Theradiag FIDIS CELIAC DGP	-	-	-	-	-	96.0	96.0	-	1
All	425.5	475.0	151.4	35.6	33.0	96.0	624.0	1	22









Sample S002 | DGPAbA, U/ml




Methodics	Negative	Total
EIA Gliadin DA, TestLine	1	1
EliA/ImmunoCAP, Phadia	17	17
ELISA, Euroimmun	2	2
ELISA, Inova	1	1
ELISA, Orgentec	3	3
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgA	1	1
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
TestLine CLIA Gliadin DA IgA	1	1
TestLine EIA Gliadin DA IgA	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	29	29

Sample S002 | DGPAbG, U/ml

Methodics	Positive	Total
Bio-Rad BioPlex 2200 Celiac IgG	1	1
CIA, Inova	1	1
EIA Gliadin DA, TestLine	1	1
EliA/ImmunoCAP, Phadia	24	24
ELISA, Euroimmun	2	2
ELISA, Inova	2	2
ELISA, Orgentec	4	4
Euroimmun EUROLINE Autoimmune Gastrointestinal Diseases IgG	1	1
IFA Euroimmun EUROPLUS Endomysium / Gliadin (GAF-3X)	1	1
TestLine CLIA Gliadin DA IgG	1	1
TestLine EIA Gliadin DA IgG	1	1
Theradiag FIDIS CELIAC DGP	1	1
Total	40	40

Methodics	x_{pt}	Median	sd	CV%	SEM	min	max	Outliers	n
Bio-Rad BioPlex 2200 Celiac IgG	-	-	-	-	-	251.0	251.0	-	1
EIA Gliadin DA, TestLine	-	-	-	-	-	200.0	200.0	-	1
EliA/ImmunoCAP, Phadia	338.5	302.5	182.0	53.8	74.3	138.0	685.0	-	6
ELISA, Inova	-	-	-	-	-	150.0	150.0	-	1
ELISA, Orgentec	-	-	-	-	-	359.0	359.0	-	1
TestLine CLIA Gliadin DA IgG	-	-	-	-	-	78.8	78.8	-	1
Theradiag FIDIS CELIAC DGP	-	-	-	-	-	138.0	138.0	-	1
All	267.3	275.5	158.2	59.2	45.7	78.8	685.0	-	12





Sample S002 | Total IgA concentration of the sample

	n
Sufficient to determine specific coeliac IgA antibodies	1
Probably insufficient to determine specific coeliac IgA antibodies	20
Total IgA concentration was not determined	19
Total	40

Report info**Participants**

58 participants from 14 countries.

Report info

Qualitative and quantitative results are presented in the same report. Always compare your results to those obtained with the same test kit.

The qualitative results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green colour and laboratory's own result with a black radio button .

The quantitative results from the positive specimens are presented as histograms. Quantitative results reported with < or > -signs are not processed. Results reported as ratios, titres, absorbances and without a unit are manually removed and not statistically processed.

Assigned values (target values) are mean of the results where results deviating more than ± 3 standard deviation from the median are removed. The standard uncertainty (u) of the assigned value is reported as standard error of the mean (SEM). Additionally, if the measurement uncertainty of the target value is large an automatic text is printed on the report: "The uncertainty of the assigned value is not negligible, and evaluations could be affected". In case the client's result is the only one in the method group, no assigned value will be calculated, no target area shown, and no statistics calculated.

In participant specific report your own result is shown with an orange dot. The target area is presented as a yellow area in the picture. In the history graphs you are able to see your performance graphically with both against the assigned value (xpt) and the z-score area of -2 ... +2.

If you have not reported any results you will get a note: "You have not responded in time, only global report is available".

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EOA Coordinator.

External Quality Assessment Scheme

Coeliac disease, antibodies Round 1, 2023

Specimens

Samples of this EQA round were human plasma or serum. Based on the pre-testing and the results obtained in the round, the samples were homogeneous, stable and suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The accepted results were as follows:

Sample S001 (LQ717423011)

EMAAbA	Positive
EMAAbG	Positive
tTGAAbA	Positive
tTGAAbG	Positive
DGPAbA	Positive
DGPAbG	Positive

Total IgA concentration of the sample: sufficient to determine specific coeliac IgA antibodies.

Sample S002 (LQ717423012)

EMAAbA	Negative
EMAAbG	Positive
tTGAAbA	Negative
tTGAAbG	Positive
DGPAbA	Negative
DGPAbG	Positive

Total IgA concentration of the sample: insufficient to determine specific coeliac IgA antibodies.

Pre-test methods: EliA Celikey (tTG) IgA/IgG Well, EliA Gliadin DP IgA/IgG Well. Endomysium antibodies (EMA): Euroimmun IIFT (monkey liver).

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – Expert

In this EQA round, sample S001 was positive for all coeliac disease specific antibodies while S002 was positive only for coeliac disease specific IgG antibodies. Total IgA of S002 was insufficient for determining specific IgA antibodies.

As before, the concentration results were scattered depending on the method used for the analyses. The most difficult analyte in this EQA round was DGPAbA in sample S001. A fifth of the participants reported S001 as negative for this analyte while the majority reported it as positive. Pre-testing gave a low positive result. The results of the other analytes were significantly more similar.

All participants reported the sample S002 as negative for coeliac disease specific IgA class antibodies and positive for IgG class antibodies (with one exception for tTGAAbG).

2023-03-31

FINAL REPORT

Product no. 5940

Subcontracting: Sample pretesting

Samples sent	2023-02-21
Round closed	2023-03-17
Expected results	2023-03-21
Final report	2023-03-31

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Mira Saarinen
mira.h.saarinen@labquality.fi

Expert

PhD, Microbiologist
Annukka Pietikäinen
Turku University Hospital
Turku, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



Only the analysis phase
is accredited.



As a reminder: The samples of the Coeliac disease EQA rounds should be analyzed as such without diluting the samples. Results which are over the detection limit of the assay should be reported using ">" symbol.

Exceptions

No exceptions

Annex

The number of results above (>) the detection limits of the methods reported for samples by method and analyte. (Annex 1).

End of report

Annex 1. The number of results above (>) the detection limits of the methods reported for samples by method and analyte.

	<i>tTGAbA</i>	<i>tTGAbG</i>	<i>DGPAbA</i>	<i>DGPAbG</i>
<i>EliA/ImmunoCAP, Phadia</i>		1/18 participants (S002)		15/23 participants (S001) 17/23 participants (S002)
<i>Chorus tTG</i>	1/3 participants (S001)	1/1 participants (S001) 1/1 participants (S002)		
<i>ELISA, Euroimmun</i>	3/4 participants (S001)			2/2 participants (S001) 2/2 participants (S002)
<i>ELISA, Orgentec</i>		4/6 participants (S002)		3/4 participants (S001) 3/4 participants (S002)
<i>CIA, Inova</i>				1/1 participants (S002)